Tokyo, Sept 30, 2009 (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they had submitted an application for approval of Crohn's disease as an additional indication for Humira(R) (adalimumab), a fully human monoclonal anti-TNF-alpha antibody jointly developed by the two companies.
